# A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

> **NCT05105048** · PHASE1 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Cytomegalovirus Infection

## Interventions

- **BIOLOGICAL:** mRNA-1647
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05105048
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-08
- **Primary completion:** 2023-08-10
- **Final completion:** 2023-08-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05105048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05105048, "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05105048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*